Raphael Pharmaceutical Stock Current Liabilities

RAPH Stock   0.26  0.00  0.00%   
Raphael Pharmaceutical fundamentals help investors to digest information that contributes to Raphael Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Raphael OTC Stock. The fundamental analysis module provides a way to measure Raphael Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Raphael Pharmaceutical otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Raphael Pharmaceutical OTC Stock Current Liabilities Analysis

Raphael Pharmaceutical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition
In accordance with the recently published financial statements, Raphael Pharmaceutical has a Current Liabilities of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Liabilities (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Raphael Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.
Raphael Pharmaceutical is currently under evaluation in current liabilities category among its peers.

Raphael Fundamentals

About Raphael Pharmaceutical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Raphael OTC Stock

Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.